SCHEMBL5111951

SCHEMBL5111951

O=C(Nc1cccc([N+](=O)[O-])c1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX1 P51575 2/20 0.65
SLC10A6 Q3KNW5 3/20 0.58
SLC10A2 Q12908 2/20 0.58
SLC10A1 Q14973 2/20 0.58
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
MAPK1 P28482 1/20 0.55
HTT P42858 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
KCNA5 P22460 1/20 0.53
IDH1 O75874 1/20 0.53
CASP3 P42574 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
SENP6 Q9GZR1 1/20 0.53
GPR17 Q13304 1/20 0.52
GPR27 Q9NS67 4/20 0.52
FLT1 P17948 1/20 0.51
FLT4 P35916 1/20 0.51
KDR P35968 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5126770 0.88 SLC10A6 (0.67) P2RX1SLC10A6SLC10A2SLC10A1MEN1
SCHEMBL490913 0.85 SLC10A6 (0.64) SLC10A6SLC10A2SLC10A1MEN1KMT2A
SCHEMBL5115547 0.84 SMN1; SMN2 (0.64) SLC10A6SLC10A2SLC10A1MEN1KMT2A
SCHEMBL20560666 0.83 DDX3X (0.57) P2RX1SLC10A6SLC10A2SLC10A1MEN1
SCHEMBL20560565 0.83 MEN1 (0.56) P2RX1SLC10A6SLC10A2SLC10A1MEN1
SCHEMBL6754585 0.83 SLC10A6 (0.81) P2RX1SLC10A6SLC10A2SLC10A1MEN1
SCHEMBL491680 0.83 SLC10A6 (0.60) SLC10A6SLC10A2SLC10A1MEN1KMT2A
SCHEMBL492519 0.83 SLC10A6 (0.60) P2RX1SLC10A6SLC10A2SLC10A1MEN1
SCHEMBL5119957 0.83 SLC10A6 (0.60) SLC10A6SLC10A2SLC10A1MEN1KMT2A
SCHEMBL491757 0.82 SLC10A6 (0.61) SLC10A6SLC10A2SLC10A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351703-B2 Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-01 US disclosed
EP-1095015-B1 SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS AVENTIS PHARMA GMBH (DE) 2005-06-01 EP disclosed
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2005-04-14 US disclosed
US-6809089-B2 FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISORDERS SUCH AS HIGH BLOOD PRESSURE, ANGINA PECTORIS, CARDIAC INSUFFICIENCY, THROMBOSES OR ATHEROSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-10-26 US disclosed
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 US disclosed
US-6548547-B1 Cardiovascular disorders; hypotensive agents, antiasthmatics, cognition activators AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1A2 P2RX1 222/4885SLC10A6 2987/4885SLC10A2 1391/4885
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1B2 P2RX1 428/4885SLC10A6 3299/4885SLC10A2 1534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.